You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCaspofungin
Accession NumberDB00520  (APRD00199)
TypeSmall Molecule
GroupsApproved
DescriptionCaspofungin (brand name Cancidas worldwide) is an antifungal drug, the first of a new class termed the echinocandins from Merck & Co., Inc. It shows activity against infections with Aspergillus and Candida, and works by inhibiting β(1,3)-D-Glucan of the fungal cell wall. Caspofungin is administered intravenously.
Structure
Thumb
Synonyms
(4R,5S)-5-((2-Aminoethyl)amino)-N(2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(P-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide
1-[(4R,5S)-5-[(2-Aminoethyl)amino]-N(2)-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin b0
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cancidasinjection, powder, lyophilized, for solution5 mg/mLintravenousMerck Sharp & Dohme Corp.2001-01-26Not applicableUs
CancidasPowder for concentrate for solution for infusion50 mgIntravenous useMerck Sharp & Dohme Ltd2001-10-24Not applicableEu
Cancidasinjection, powder, lyophilized, for solution7 mg/mLintravenousMerck Sharp & Dohme Corp.2001-01-26Not applicableUs
CancidasPowder for concentrate for solution for infusion70 mgIntravenous useMerck Sharp & Dohme Ltd2001-10-24Not applicableEu
Cancidaspowder for solution50 mgintravenousMerck Canada Inc2001-08-23Not applicableCanada
Cancidaspowder for solution70 mgintravenousMerck Canada Inc2001-10-23Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Caspofungin acetate
179463-17-3
Thumb
  • InChI Key: OGUJBRYAAJYXQP-LLXMLGLCSA-N
  • Monoisotopic Mass: 1212.68532094
  • Average Mass: 1213.417
DBSALT000020
Categories
UNIIF0XDI6ZL63
CAS number162808-62-0
WeightAverage: 1093.3131
Monoisotopic: 1092.643062196
Chemical FormulaC52H88N10O15
InChI KeyInChIKey=JYIKNQVWKBUSNH-OGZDCFRISA-N
InChI
InChI=1S/C52H88N10O15/c1-5-28(2)24-29(3)12-10-8-6-7-9-11-13-39(69)56-34-26-38(68)46(55-22-21-54)60-50(75)43-37(67)19-23-61(43)52(77)41(36(66)18-20-53)58-49(74)42(45(71)44(70)31-14-16-32(64)17-15-31)59-48(73)35-25-33(65)27-62(35)51(76)40(30(4)63)57-47(34)72/h14-17,28-30,33-38,40-46,55,63-68,70-71H,5-13,18-27,53-54H2,1-4H3,(H,56,69)(H,57,72)(H,58,74)(H,59,73)(H,60,75)/t28?,29?,30-,33-,34+,35+,36-,37+,38-,40+,41+,42+,43+,44+,45+,46+/m1/s1
IUPAC Name
N-[(3S,6S,9S,11R,15S,18S,20R,21S,24S,25S)-3-[(1R)-3-amino-1-hydroxypropyl]-21-[(2-aminoethyl)amino]-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,25-trihydroxy-15-[(1R)-1-hydroxyethyl]-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0⁹,¹³]heptacosan-18-yl]-10,12-dimethyltetradecanamide
SMILES
CCC(C)CC(C)CCCCCCCCC(=O)N[[email protected]]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[[email protected]](O)[C@@H](O)C1=CC=C(O)C=C1)[[email protected]](O)CCN
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as cyclic peptides. These are compounds containing a cyclic moiety bearing a peptide backbone.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentCyclic peptides
Alternative Parents
Substituents
  • Cyclic alpha peptide
  • Phenol
  • Benzenoid
  • Monocyclic benzene moiety
  • Cyclic carboximidic acid
  • Tertiary carboxylic acid amide
  • Pyrrolidine
  • 1,3-aminoalcohol
  • Tertiary amine
  • Secondary alcohol
  • Polyol
  • Lactam
  • Carboxamide group
  • 1,2-diol
  • Azacycle
  • Organoheterocyclic compound
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Secondary amine
  • Secondary aliphatic amine
  • Carboximidic acid derivative
  • Carboximidic acid
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Primary aliphatic amine
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of esophageal candidiasis and invasive aspergillosis in patients who are refractory to or intolerant of other therapies.
PharmacodynamicsCaspofungin is an antifungal drug, and belongs to a new class termed the echinocandins. It is used to treat Aspergillus and Candida infection, and works by inhibiting cell wall synthesis. Antifungals in the echinocandin class inhibit the synthesis of glucan in the cell wall, probably via the enzyme 1,3-beta glucan synthase. There is a potential for resistance development to occur, however in vitro resistance development to Caspofungin by Aspergillus species has not been studied.
Mechanism of actionCaspofungin inhibits the synthesis of beta-(1,3)-D-glucan, an essential component of the cell wall of Aspergillus species and Candida species. beta-(1,3)-D-glucan is not present in mammalian cells. The primary target is beta-(1,3)-glucan synthase.
Related Articles
Absorption92% tissue distribution within 36-48 hours after intravenous infusion
Volume of distributionNot Available
Protein binding97%
Metabolism

Metabolized slowly by hydrolysis and N-acetylation

Route of eliminationAfter single intravenous administration of [3H] caspofungin acetate, excretion of caspofungin and its metabolites in humans was 35% of dose in feces and 41% of dose in urine.
Half life9-11 hours
Clearance
  • 12 mL/min [After single IV administration]
ToxicitySide effects include rash, swelling, and nausea (rare)
Affected organisms
  • Aspergillis, Candida and other fungi
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.7566
Blood Brain Barrier-0.96
Caco-2 permeable-0.8091
P-glycoprotein substrateSubstrate0.8694
P-glycoprotein inhibitor INon-inhibitor0.9653
P-glycoprotein inhibitor IINon-inhibitor0.9174
Renal organic cation transporterNon-inhibitor0.9379
CYP450 2C9 substrateNon-substrate0.831
CYP450 2D6 substrateNon-substrate0.8166
CYP450 3A4 substrateNon-substrate0.51
CYP450 1A2 substrateNon-inhibitor0.9389
CYP450 2C9 inhibitorNon-inhibitor0.9161
CYP450 2D6 inhibitorNon-inhibitor0.8904
CYP450 2C19 inhibitorNon-inhibitor0.875
CYP450 3A4 inhibitorNon-inhibitor0.9682
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9781
Ames testNon AMES toxic0.7398
CarcinogenicityNon-carcinogens0.8315
BiodegradationNot ready biodegradable0.9683
Rat acute toxicity2.9344 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9637
hERG inhibition (predictor II)Non-inhibitor0.716
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Merck and co inc
Packagers
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionintravenous5 mg/mL
Injection, powder, lyophilized, for solutionintravenous7 mg/mL
Powder for concentrate for solution for infusionIntravenous use50 mg
Powder for concentrate for solution for infusionIntravenous use70 mg
Powder for solutionintravenous50 mg
Powder for solutionintravenous70 mg
Prices
Unit descriptionCostUnit
Cancidas iv 70 mg vial421.06USD vial
Cancidas iv 50 mg vial405.25USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2118757 No2002-05-142014-03-10Canada
CA2251928 No2003-06-172017-04-15Canada
US5378804 No1993-03-162013-03-16Us
US5514650 Yes1995-07-262015-07-26Us
US5952300 Yes1997-09-282017-09-28Us
US6136783 Yes1997-09-282017-09-28Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP0Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.367 mg/mLALOGPS
logP0.17ALOGPS
logP-4.8ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)8.75ChemAxon
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count18ChemAxon
Hydrogen Donor Count16ChemAxon
Polar Surface Area412.03 Å2ChemAxon
Rotatable Bond Count23ChemAxon
Refractivity278.78 m3·mol-1ChemAxon
Polarizability117.52 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Johannes Ludescher, Ingolf Macher, Ole Storm, Stephan Bertel, “Process and Intermediates for the Synthesis of Caspofungin.” U.S. Patent US20080319162, issued December 25, 2008.

US20080319162
General References
  1. Sucher AJ, Chahine EB, Balcer HE: Echinocandins: the newest class of antifungals. Ann Pharmacother. 2009 Oct;43(10):1647-57. doi: 10.1345/aph.1M237. Epub 2009 Sep 1. [PubMed:19724014 ]
  2. Morrison VA: Caspofungin: an overview. Expert Rev Anti Infect Ther. 2005 Oct;3(5):697-705. [PubMed:16207161 ]
  3. McCormack PL, Perry CM: Caspofungin: a review of its use in the treatment of fungal infections. Drugs. 2005;65(14):2049-68. [PubMed:16162025 ]
  4. Morris MI, Villmann M: Echinocandins in the management of invasive fungal infections, part 1. Am J Health Syst Pharm. 2006 Sep 15;63(18):1693-703. [PubMed:16960253 ]
  5. Morris MI, Villmann M: Echinocandins in the management of invasive fungal infections, Part 2. Am J Health Syst Pharm. 2006 Oct 1;63(19):1813-20. [PubMed:16990627 ]
External Links
ATC CodesJ02AX04
AHFS Codes
  • 08:14.16
PDB EntriesNot Available
FDA labelDownload (87.9 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Caspofungin.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Caspofungin.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Caspofungin.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Caspofungin.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Caspofungin.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Caspofungin.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Caspofungin.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Caspofungin.
AmlodipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Amlodipine.
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Caspofungin.
AmrinoneThe risk or severity of adverse effects can be increased when Caspofungin is combined with Amrinone.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Caspofungin.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Caspofungin.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Caspofungin.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Caspofungin.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Caspofungin.
AzelnidipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Azelnidipine.
AzimilideThe risk or severity of adverse effects can be increased when Caspofungin is combined with Azimilide.
BarnidipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Barnidipine.
BenidipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Benidipine.
BepridilThe risk or severity of adverse effects can be increased when Caspofungin is combined with Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Caspofungin.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Caspofungin.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Caspofungin.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Caspofungin.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Caspofungin.
BuspironeThe metabolism of Buspirone can be decreased when combined with Caspofungin.
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Caspofungin.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Caspofungin.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Caspofungin.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Caspofungin.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Caspofungin.
CarbamazepineThe serum concentration of Caspofungin can be decreased when it is combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Caspofungin.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Caspofungin.
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Caspofungin.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Caspofungin.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Caspofungin.
CilnidipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Cilnidipine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Caspofungin.
CinnarizineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Cinnarizine.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Caspofungin.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Caspofungin.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Caspofungin.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Caspofungin.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Caspofungin.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Caspofungin.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Caspofungin.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Caspofungin.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Caspofungin.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Caspofungin.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Caspofungin.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Caspofungin.
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Caspofungin.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Caspofungin.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Caspofungin.
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Caspofungin.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Caspofungin.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Caspofungin.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Caspofungin.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Caspofungin.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Caspofungin.
DarodipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Darodipine.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Caspofungin.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Caspofungin.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Caspofungin.
DexamethasoneThe serum concentration of Caspofungin can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Caspofungin.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Caspofungin.
DidanosineDidanosine can cause a decrease in the absorption of Caspofungin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Caspofungin.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Caspofungin.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Caspofungin.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Caspofungin.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Caspofungin.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Caspofungin.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Caspofungin.
DofetilideThe metabolism of Dofetilide can be decreased when combined with Caspofungin.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Caspofungin.
DotarizineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Dotarizine.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Caspofungin.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Caspofungin.
EfavirenzThe serum concentration of Caspofungin can be decreased when it is combined with Efavirenz.
EfonidipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Efonidipine.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Caspofungin.
EperisoneThe risk or severity of adverse effects can be increased when Caspofungin is combined with Eperisone.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Caspofungin.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Caspofungin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Caspofungin.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Caspofungin.
EstriolThe serum concentration of Estriol can be increased when it is combined with Caspofungin.
EstroneThe serum concentration of Estrone can be increased when it is combined with Caspofungin.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Caspofungin.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Caspofungin.
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Caspofungin.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Caspofungin.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Caspofungin.
FelodipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Felodipine.
FendilineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Fendiline.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Caspofungin.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Caspofungin.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Caspofungin.
FlunarizineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Flunarizine.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Caspofungin.
FosphenytoinThe serum concentration of Caspofungin can be decreased when it is combined with Fosphenytoin.
GabapentinThe risk or severity of adverse effects can be increased when Caspofungin is combined with Gabapentin.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Caspofungin.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Caspofungin.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Caspofungin.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Caspofungin.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Caspofungin.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Caspofungin.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Caspofungin.
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Caspofungin.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Caspofungin.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Caspofungin.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Caspofungin.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Caspofungin.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Caspofungin.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Caspofungin.
IsradipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Isradipine.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Caspofungin.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Caspofungin.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Caspofungin.
LacidipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Lacidipine.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Caspofungin.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Caspofungin.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Caspofungin.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Caspofungin.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Caspofungin.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Caspofungin.
LercanidipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Lercanidipine.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Caspofungin.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Caspofungin.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Caspofungin.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Caspofungin.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Caspofungin.
LosartanThe metabolism of Losartan can be decreased when combined with Caspofungin.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Caspofungin is combined with Magnesium Sulfate.
ManidipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Manidipine.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Caspofungin.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Caspofungin.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Caspofungin.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Caspofungin.
MibefradilThe risk or severity of adverse effects can be increased when Caspofungin is combined with Mibefradil.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Caspofungin.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Caspofungin.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Caspofungin.
MorphineThe serum concentration of Morphine can be increased when it is combined with Caspofungin.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Caspofungin.
NadololThe serum concentration of Nadolol can be increased when it is combined with Caspofungin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Caspofungin.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Caspofungin.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Caspofungin.
NevirapineThe serum concentration of Caspofungin can be decreased when it is combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Caspofungin.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Caspofungin.
NiguldipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Niguldipine.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Caspofungin.
NiludipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Niludipine.
NilvadipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Nilvadipine.
NimesulideThe risk or severity of adverse effects can be increased when Caspofungin is combined with Nimesulide.
NimodipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Nimodipine.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Caspofungin.
NisoldipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Nisoldipine.
NitrendipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Nitrendipine.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Caspofungin.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Caspofungin.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Caspofungin.
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Caspofungin.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Caspofungin.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Caspofungin.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Caspofungin.
PerhexilineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Perhexiline.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Caspofungin.
PhenytoinThe serum concentration of Caspofungin can be decreased when it is combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Caspofungin.
PimozideCaspofungin may increase the arrhythmogenic activities of Pimozide.
PinaveriumThe risk or severity of adverse effects can be increased when Caspofungin is combined with Pinaverium.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Caspofungin.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Caspofungin.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Caspofungin.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Caspofungin.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Caspofungin.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Caspofungin.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Caspofungin.
PregabalinThe risk or severity of adverse effects can be increased when Caspofungin is combined with Pregabalin.
PrenylamineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Prenylamine.
ProgesteroneThe therapeutic efficacy of Progesterone can be decreased when used in combination with Caspofungin.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Caspofungin.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Caspofungin.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Caspofungin.
QuinidineThe metabolism of Quinidine can be decreased when combined with Caspofungin.
QuinineThe serum concentration of Quinine can be increased when it is combined with Caspofungin.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Caspofungin.
RanolazineThe metabolism of Ranolazine can be decreased when combined with Caspofungin.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Caspofungin.
RifampicinThe serum concentration of Caspofungin can be decreased when it is combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Caspofungin.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Caspofungin.
RisedronateThe risk or severity of adverse effects can be increased when Caspofungin is combined with Risedronate.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Caspofungin.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Caspofungin.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Caspofungin.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Caspofungin.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Caspofungin.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Caspofungin.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Caspofungin.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Caspofungin.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Caspofungin.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Caspofungin.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Caspofungin.
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Caspofungin.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Caspofungin.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Caspofungin.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Caspofungin.
SucralfateSucralfate can cause a decrease in the absorption of Caspofungin resulting in a reduced serum concentration and potentially a decrease in efficacy.
SunitinibThe metabolism of Sunitinib can be decreased when combined with Caspofungin.
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Caspofungin.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Caspofungin.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Caspofungin.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Caspofungin.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Caspofungin.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Caspofungin.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Caspofungin.
TimololThe serum concentration of Timolol can be increased when it is combined with Caspofungin.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Caspofungin is combined with Tolfenamic Acid.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Caspofungin.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Caspofungin.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Caspofungin.
TranilastThe risk or severity of adverse effects can be increased when Caspofungin is combined with Tranilast.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Caspofungin.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Caspofungin.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Caspofungin.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Caspofungin.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Caspofungin.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Caspofungin.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Caspofungin.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Caspofungin.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Caspofungin.
XylometazolineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Xylometazoline.
ZiconotideThe risk or severity of adverse effects can be increased when Caspofungin is combined with Ziconotide.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Caspofungin.
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Caspofungin.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Aspergillus niger (strain CBS 513.88 / FGSC A1513)
Pharmacological action
yes
Actions
inhibitor
General Function:
1,3-beta-d-glucan synthase activity
Specific Function:
Catalytic subunit of the 1,3-beta-glucan synthase. Synthesizes 1,3-beta-glucan, a major structural component of the cell wall. Involved in cell wall synthesis, maintenance and cell wall remodeling (By similarity).
Gene Name:
fksA
Uniprot ID:
A2QLK4
Molecular Weight:
216972.8 Da
References
  1. Sucher AJ, Chahine EB, Balcer HE: Echinocandins: the newest class of antifungals. Ann Pharmacother. 2009 Oct;43(10):1647-57. doi: 10.1345/aph.1M237. Epub 2009 Sep 1. [PubMed:19724014 ]
  2. Morrison VA: Caspofungin: an overview. Expert Rev Anti Infect Ther. 2005 Oct;3(5):697-705. [PubMed:16207161 ]
  3. McCormack PL, Perry CM: Caspofungin: a review of its use in the treatment of fungal infections. Drugs. 2005;65(14):2049-68. [PubMed:16162025 ]
  4. Morris MI, Villmann M: Echinocandins in the management of invasive fungal infections, part 1. Am J Health Syst Pharm. 2006 Sep 15;63(18):1693-703. [PubMed:16960253 ]
  5. Morris MI, Villmann M: Echinocandins in the management of invasive fungal infections, Part 2. Am J Health Syst Pharm. 2006 Oct 1;63(19):1813-20. [PubMed:16990627 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Sandhu P, Lee W, Xu X, Leake BF, Yamazaki M, Stone JA, Lin JH, Pearson PG, Kim RB: Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos. 2005 May;33(5):676-82. Epub 2005 Feb 16. [PubMed:15716364 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Sandhu P, Lee W, Xu X, Leake BF, Yamazaki M, Stone JA, Lin JH, Pearson PG, Kim RB: Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos. 2005 May;33(5):676-82. Epub 2005 Feb 16. [PubMed:15716364 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Sandhu P, Lee W, Xu X, Leake BF, Yamazaki M, Stone JA, Lin JH, Pearson PG, Kim RB: Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos. 2005 May;33(5):676-82. Epub 2005 Feb 16. [PubMed:15716364 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. Sandhu P, Lee W, Xu X, Leake BF, Yamazaki M, Stone JA, Lin JH, Pearson PG, Kim RB: Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos. 2005 May;33(5):676-82. Epub 2005 Feb 16. [PubMed:15716364 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B3
Uniprot ID:
Q9NPD5
Molecular Weight:
77402.175 Da
References
  1. Sandhu P, Lee W, Xu X, Leake BF, Yamazaki M, Stone JA, Lin JH, Pearson PG, Kim RB: Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos. 2005 May;33(5):676-82. Epub 2005 Feb 16. [PubMed:15716364 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 26, 2016 03:28